Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation

被引：0
|
作者：
Torbjørn Wisløff
Gunhild Hagen
Marianne Klemp
机构：
[1] Norwegian Knowledge Centre for the Health Services,Department of Biostatistics, Epidemiology and Health Economics
[2] Oslo University Hospital,Department of Health Management and Health Economics
[3] University of Oslo,Department of Public Health and General Practice
[4] Norwegian University of Science and Technology,Department of Pharmacology
[5] University of Oslo,undefined
来源：
PharmacoEconomics | 2014年 / 32卷
关键词：
Warfarin; International Normalize Ratio; Dabigatran; Rivaroxaban; Oral Anticoagulant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：601 / 612
页数：11
相关论文
共 50 条
  • [1] Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
    Wisloff, Torbjorn
    Hagen, Gunhild
    Klemp, Marianne
    [J]. PHARMACOECONOMICS, 2014, 32 (06) : 601 - 612
  • [2] ECONOMIC EVALUATION OF DABIGATRAN ETEXILATE VERSUS WARFARIN, RIVAROXABAN AND APIXABAN IN STROKE PREVENTION IN ATRIAL FIBRILATION
    Huicochea-Bartelt, J. L.
    Gay-Molina, J.
    Ortiz-Blas, L. A.
    Herran, S.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A141 - A141
  • [3] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Harrington, Amanda R.
    Armstrong, Edward P.
    Nolan, Paul E., Jr.
    Malone, Daniel C.
    [J]. STROKE, 2013, 44 (06) : 1676 - +
  • [4] New Anticoagulants (Dabigatran, Apixaban, Rivaroxaban) for Stroke Prevention in Atrial Fibrillation
    Aguilar, Maria I.
    Kuo, Ruth S.
    Freeman, William D.
    [J]. NEUROLOGIC CLINICS, 2013, 31 (03) : 659 - +
  • [5] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Chieh-Yu Liu
    Hui-Chun Chen
    [J]. Clinical Drug Investigation, 2017, 37 : 285 - 293
  • [6] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Liu, Chieh-Yu
    Chen, Hui-Chun
    [J]. CLINICAL DRUG INVESTIGATION, 2017, 37 (03) : 285 - 293
  • [7] COST-EFFECTIVENESS OF EDOXABAN, APIXABAN, RIVAROXABAN AND DABIGATRAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
    Marchetti, M.
    Liberato, N. L.
    Rognoni, C.
    Quaglini, S.
    [J]. HAEMATOLOGICA, 2014, 99 : 487 - 487
  • [8] COST EFFECTIVENESS OF APIXABAN, DABIGATRAN RIVAROXABAN AND WARFARIN FOR ATRIAL FIBRILLATION IN GUATEMALA
    Garita, M.
    Peralta, M.
    Gordillo, D., I
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A115 - A115
  • [9] COST EFFECTIVENESS EVALUATION OF APIXABAN, DABIGATRAN RIVAROXABAN AND WARFARIN FOR PREVENTION OF TROMBOEMBOLISM IN PATIENTS WITH ATRIAL FIBRILLATION IN TRINIDAD AND TOBAGO
    Garita, M.
    Peralta, M.
    Dookie, T. A.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A116 - A117
  • [10] LIFETIME COSTS AND LIFE-YEARS GAINED ASSOCIATED WITH APIXABAN, DABIGATRAN, RIVAROXABAN, AND WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
    Harrington, A. R.
    Armstrong, E. P.
    Nolan, P.
    Malone, D. C.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A286 - A286
12345